Back to results
US 2026/0109671 A1Published application
Beta adrenergic agonist and methods of using the same
AssigneeCuraSen Therapeutics, Inc.
InventorsAnthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
Claims20
A pharmaceutical composition comprising about 10 pg to 100 mg of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1′ is halogen, —R′, —CN, or —NO2;
- each R′ is an optionally substituted C1-6 aliphatic;
- and
- R2′, R3′, and R4′ are each independently halogen, —R′, —CN, —NO2, —OR′, or —NR′2, or
- R2′ and R3′ together with the carbon form an optionally substituted 3-7 membered cycloalkyl or heterocycle ring, as a unit dosage form.
4 more elements
A method of treating a disease associated with an adrenergic receptor by slowing down, lessening symptoms of, and/or halting the progression of the disease in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1′ is halogen, —R′, —CN, or —NO2;
- each R′ is an optionally substituted C1-6 aliphatic;
- and
- R2′, R3′, and R4′ are each independently halogen, —R′, —CN, —NO2, —OR′, or —NR′2, or
- R2′ and R3′ together with the carbon form an optionally substituted 3-7 membered cycloalkyl or heterocycle ring,
- thereby treating the disease in the subject.
5 more elements
Dependencies are inferred from the claim text.